Streetbeat News

MSSTF

Mindset Pharma Inc

Industry

Pharmaceutical Preparation Manufacturing

Open

0.54

Mkt cap

55M

Volume

900

High

0.54

P/E Ratio

-13.45

52-wk high

0.56

Low

0.54

Div yield

N/A

52-wk low

0.16

A new study highlights the potential of psilocybin-assisted therapy for treating depression, with millions of Americans potentially benefiting. Companies like Compass Pathways, Atai Life Sciences, and Mindset Pharma are developing psilocybin-based treatments, anticipating significant market growth if FDA approval is granted.

Portfolio Pulse from Juan Spínelli

October 07, 2024 | 8:23 pm

Reunion Neuroscience has received FDA clearance to begin a Phase 2 study of RE104, a novel serotonergic psychedelic compound for treating postpartum depression (PPD). The company, which recently went private after listing on NASDAQ, will commence its multicenter, randomized, double-blind, placebo-controlled trial in Q4 2023. The trial will evaluate the safety and efficacy of a single subcutaneous dose of RE104 in adult female patients with PPD. RE104 is protected under U.S. patent No. 11,292,765, but there's an ongoing legal battle over the compound's creative ownership, including a lawsuit filed by Reunion against Mindset Pharma.

Portfolio Pulse from Lara Goldstein

September 18, 2023 | 8:30 pm

Several mergers and acquisitions have been announced in the psychedelics sector. Cybin (NYSE:CYBN) is acquiring Small Pharma (OTC:DMTTF), Silo Wellness (OTC:SILFF) is buying NUGL Inc./Kaya Group (OTC:NUGL), and Mindset Pharma (OTC:MSSTF) is being acquired by Otsuka America Inc., part of Otsuka Holdings (OTC:OTSKF). Additionally, Psyched Wellness (OTC:PSYCF) is set to receive $7.5M in financing. The AdvisorShares Psychedelics ETF (NYSE:PSIL) has seen a slight increase in its share price.

Portfolio Pulse from Lara Goldstein

September 05, 2023 | 2:08 pm

Mindset Pharma (OTC:MSSTF) has agreed to acquire all outstanding shares of Otsuka America Inc., the U.S. arm of Otsuka Pharmaceutical Co., for approximately $60 million. The transaction is expected to close on or around October 19, 2023. This acquisition follows Mindset's partnership with Otsuka’s McQuade Center for Strategic Research and Development (MSRD) in January 2022. The deal is seen as a way to maximize Mindset’s IP portfolio and assets value.

Portfolio Pulse from Lara Goldstein

August 31, 2023 | 5:54 pm

Terran Biosciences has filed a patent application for solid forms of 4-OH-DiPT hemiglutarate, a psychedelic compound, amidst an ongoing court battle between Reunion Neuroscience (NASDAQ:REUN) and Mindset Pharma (OTC:MSSTF) over similar claims. Terran's application claims priority back to six provisional applications, including four filed just a week after the broad nature of RE104, Reunion's lead drug candidate, was disclosed.

Portfolio Pulse from Lara Goldstein

July 19, 2023 | 12:47 am

Reunion Neuroscience (NASDAQ:REUN) is set to go private following a final court approval. The company is closing on its take-private transaction with MPM BioImpact affiliates, with shareholders approving the arrangement plan. The acquisition of Reunion in an all-cash transaction of $13.1 million is expected to close on or about July 21, 2023. Reunion was split from Field Trip Health in mid-2022 and has been developing a novel serotonergic psychedelic compound, RE104, as a potential treatment for postpartum depression.

Portfolio Pulse from Lara Goldstein

July 17, 2023 | 9:04 pm

The Multidisciplinary Association for Psychedelic Studies (MAPS) sponsored a Psychedelic Science conference in Denver, attracting over 12,000 attendees. New York Mets owner Steve Cohen announced a $5 million grant for MAPS’ ongoing clinical studies toward FDA approval of MDMA-assisted therapy for PTSD. Toms Shoes founder Blake Mycoskie pledged to donate and invest $100 million in organizations and projects advancing psychedelic-assisted therapies. SEMRush (NYSE:SEMR) analysis revealed a shift in America's consciousness towards psychedelics and cannabis. Several companies received regulatory approvals and patents, and announced partnerships and financial results.

Portfolio Pulse from Lara Goldstein

July 04, 2023 | 2:21 pm

Reunion Neuroscience Inc. (NASDAQ:REUN) reported Q4 and full year 2023 financial results, showing a decrease in cash and cash equivalents, increased R&D and G&A expenses, and a net loss from continuing operations. The company's lead asset RE104 showed promising results in a Phase 1 analysis for the treatment of Postpartum Depression. Reunion also announced a take-private transaction by MPM BioImpact valued at approximately $13.1 million. The company faces financial risks including future expenses and expected losses, and IP risks including ongoing litigation with Mindset Pharma (OTC:MSSTF).

Portfolio Pulse from Lara Goldstein

June 29, 2023 | 5:22 pm

Mindset Pharma (OTCQB:MSSTF) has received approval from the UK's Medicines and Healthcare Products Regulatory Authority to begin a Phase 2 clinical study on its novel psilocin prodrug, MSP-1014, for the treatment of Major Depressive Disorder. The study will assess the safety and efficacy of MSP-1014 and is expected to provide a strong efficacy signal for the drug. The company's CEO sees this as a significant step towards becoming a clinical-stage biotech company focused on novel and patentable psychedelic-inspired therapeutics.

Portfolio Pulse from Lara Goldstein

June 27, 2023 | 7:54 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.